Skip to main content
Clinical Trials/CTRI/2024/11/077240
CTRI/2024/11/077240Not yet recruitingNot Applicable

Comparison of the efficacy of ondansetron alone versus ondansetron and dexamethasone in the prevention or reduction of post operative nausea and vomiting after elective surgeries under general anaesthesia

Dr Juhi Mishra1 site in 1 country100 target enrollmentStarted: November 30, 2024Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
100
Locations
1
Primary Endpoint
To compare the post operative analgesic effects between ondansetron and ondansetron with dexamethasone

Study Overview

Brief Summary

The study is designed to provide evidence that may guide clinical decision-making in managing PONV, potentially improving patient comfort and recovery outcomes. If the combination therapy proves to be more effective than ondansetron alone, it could become the preferred treatment option for preventing PONV in this patient population. Conversely, if both regimens show similar efficacy, the simpler treatment of ondansetron alone may be sufficient, with implications for reducing treatment costs and minimizing medication-related side effects.

This study seeks to add valuable insights into the optimal management strategies for PONV, contributing to enhanced patient care following elective surgeries

Study Design

Study Type
Interventional
Allocation
Na
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 60.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • 1.Able to provide informed consent 2.American Society of Anaesthesiologists (ASA) physical status I and II.

Exclusion Criteria

  • Patients with contraindications to either medication Patients requiring emergency surgery or those undergoing surgeries with known high PONV risk Severe cardiorespiratory hepatic renal neurological or endocrinal disease obesity diabetes mellitus.

Outcomes

Primary Outcomes

To compare the post operative analgesic effects between ondansetron and ondansetron with dexamethasone

Time Frame: 2hours 6hours 12hours 24hours

Secondary Outcomes

  • To identify any potential predictors of optimal dose selection and see the efficacy of both drugs in full 24 hours(2hours 6hours 12hours 24hours)

Investigators

Sponsor
Dr Juhi Mishra
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

Dr Juhi Mishra

Varun arjun medical college and rohilkhand hospital

Study Sites (1)

Loading locations...

Similar Trials